Survodutide
A dual GLP-1 and glucagon receptor agonist targeting advanced clinical weight loss and metabolic liver disease by stimulating energy use in peripheral tissues and burning deep visceral fat.
Survodutide (BI 456906) is a molecularly engineered synthetic peptide in the class of balanced dual hormone-receptor agonists, activating in a tuned way both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). The molecule is a 29-amino-acid peptide chain derived and structurally developed from the natural glucagon sequence with carefully designed local modifications, conjugated at position 10 to a fatty diacid side chain through a synthetic linker. This hybrid structure gives strong resistance to dipeptidyl peptidase-4 (DPP-4) and allows reversible binding to serum albumin, markedly extending its plasma half-life to support a single weekly subcutaneous dose. Survodutide works through two complementary physiological mechanisms. Activation of GLP-1 receptors in the digestive tract and the brain's hypothalamus directly slows gastric emptying, damps appetite and hunger centres and reduces food cravings, while supporting glucose-dependent insulin release. Activation of GCGR in liver cells and adipose tissue raises total energy expenditure, stimulates hepatic fatty-acid oxidation and inhibits triglyceride accumulation and fibrogenesis — producing a sharp reduction in hepatic fat content, treatment of non-alcoholic steatohepatitis (NASH/MASH) and record weight loss exceeding single-target analogues, with improved vascular metabolic markers.
The dual GLP-1 and glucagon agonist for dissolving liver fat, speeding calorie burning and curbing appetite with weekly efficacy
If you want to target the roots of obesity and liver fat at the same time — raising daily metabolic rate and energy use while fully controlling appetite and hunger, and fighting liver fibrosis and metabolic inflammation with one balanced molecule combining the power of the satiety and fat-burning hormones in a single weekly dose — Survodutide (BI 456906) is the latest therapeutic development in metabolic medicine and fatty-liver research.
Classification: Dual hormone-receptor agonists, combined GLP-1 and glucagon agonists, advanced therapies for obesity and fatty liver disease MASH/NASH (Dual Incretin & Glucagon Receptor Agonists / Hepatic Metabolic Modulators / Anti-Obesity & Hepatoprotective Therapeutics).
Structurally, it is a cohesive 29-amino-acid peptide conjugated to a fatty chain that gives it outstanding stability against enzymatic breakdown, allowing it to stay active in the circulation for a full week and continuously feed the receptors of the gut, brain and liver in harmony.
Picture your metabolic engine as a vehicle facing two problems: an inexhaustible surplus fuel tank (unchecked appetite) and hardened carbon deposits choking the engine (fat accumulated in the liver). Conventional drugs only close the fuel tap, whereas Survodutide is a smart dual system: it shuts the fuel tap tightly and makes the brain feel full, while igniting an advanced dissolving-and-cleansing system that burns the liver's fat deposits and restarts burning at full speed.
How it works
Survodutide binds GLP-1 receptors in the gut and the hypothalamic control centres, slowing gastric emptying and sending continuous fullness signals that suppress hunger and random overeating, while supporting controlled insulin release. In the second, complementary axis, the peptide enters liver cells and binds glucagon receptors, stimulating fatty-acid oxidation and breakdown of stored triglycerides — rapidly clearing fat accumulated in liver tissue and lowering markers of fibrosis and tissue inflammation. This simultaneous mechanism raises basal energy expenditure even at rest and produces meaningful loss of visceral and total fat mass, while improving insulin sensitivity, regulating blood sugar and lipids and providing comprehensive protection of the heart and blood vessels from the inflammatory effects of metabolic syndrome.
In clinical and research settings worldwide, Survodutide has led advanced Phase III trials (a collaboration between Boehringer Ingelheim and Zealand Pharma) and received fast-track evaluation from drug regulators as a highly promising peptide compound that has shown an unprecedented ability to clear liver fat and resolve clinical MASH inflammation beyond expectations, alongside exceptional efficacy in reducing weight in severe obesity.
Metabolic recovery and clearing deep liver fat are no longer limited to slow single-target solutions — they rest on harnessing the innate hormonal harmony that combines appetite control with activation of liver fat-burning pathways with high precision and safety.
The advanced dual agonist for fighting liver fat, activating burning and curbing appetite with a single weekly dose. Survodutide is a contemporary medical breakthrough in research on obesity, fatty-liver disease and metabolic inflammation. It belongs to the class of dual GLP-1 and glucagon receptor stimulators supporting substantial weight loss, liver-fat clearance and protection of tissues from fibrosis. Its fatty-chain-protected structure stays in the blood continuously for a full week, acting as a dual metabolic engine that calms appetite and slows gastric emptying on one side, and raises fat burning and calorie oxidation in liver cells on the other. Its unique mechanism dissolves deep visceral fat, improves insulin efficiency and repairs liver function damaged by fatty stress, achieving unprecedented clinical recovery of metabolic efficiency. Leading endocrinologists and biomedical specialists study it as a refined peptide compound that reshapes liver health and leanness — because true metabolic strength begins by activating the body's own burning and balancing pathways with an advanced molecular code that cleanses your body and restores its movement from the source.
